These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19748521)

  • 1. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia.
    Eveillard M; Soltner C; Kempf M; Saint-André JP; Lemarié C; Randrianarivelo C; Seifert H; Wolff M; Joly-Guillou ML
    J Infect; 2010 Feb; 60(2):154-61. PubMed ID: 19748521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Chiang SR; Chuang YC; Tang HJ; Chen CC; Chen CH; Lee NY; Chou CH; Ko WC
    Crit Care Med; 2009 Sep; 37(9):2590-5. PubMed ID: 19623044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii Pneumonia.
    Renckens R; Roelofs JJ; Knapp S; de Vos AF; Florquin S; van der Poll T
    J Infect Dis; 2006 Jan; 193(2):187-95. PubMed ID: 16362882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem.
    Joly-Guillou ML; Wolff M; Pocidalo JJ; Walker F; Carbon C
    Antimicrob Agents Chemother; 1997 Feb; 41(2):345-51. PubMed ID: 9021190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils.
    Qiu H; KuoLee R; Harris G; Chen W
    Microbes Infect; 2009 Oct; 11(12):946-55. PubMed ID: 19573619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice.
    KuoLee R; Harris G; Yan H; Xu HH; Conlan WJ; Patel GB; Chen W
    Vaccine; 2015 Jan; 33(1):260-7. PubMed ID: 24699469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific.
    Ong CW; Lye DC; Khoo KL; Chua GS; Yeoh SF; Leo YS; Tambyah PA; Chua AC
    Respirology; 2009 Nov; 14(8):1200-5. PubMed ID: 19909464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin.
    Pantopoulou A; Giamarellos-Bourboulis EJ; Raftogannis M; Tsaganos T; Dontas I; Koutoukas P; Baziaka F; Giamarellou H; Perrea D
    Int J Antimicrob Agents; 2007 Jan; 29(1):51-5. PubMed ID: 17189095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model.
    Lawlor MS; Hsu J; Rick PD; Miller VL
    Mol Microbiol; 2005 Nov; 58(4):1054-73. PubMed ID: 16262790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME; Fernández-Cuenca F; Docobo-Pérez F; Pachón J; Pascual A
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of high- and low-virulent strains of Chlamydia pneumoniae by their characterization in a mouse pneumonia model.
    Sommer K; Njau F; Wittkop U; Thalmann J; Bartling G; Wagner A; Klos A
    FEMS Immunol Med Microbiol; 2009 Mar; 55(2):206-14. PubMed ID: 19076226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia.
    Wu CL; Lee YL; Chang KM; Chang GC; King SL; Chiang CD; Niederman MS
    Crit Care Med; 2003 Mar; 31(3):812-7. PubMed ID: 12626989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic murine models for Acinetobacter baumannii infection.
    Luo G; Spellberg B; Gebremariam T; Bolaris M; Lee H; Fu Y; French SW; Ibrahim AS
    J Antimicrob Chemother; 2012 Jun; 67(6):1439-45. PubMed ID: 22389456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.
    van Gennip M; Moser C; Christensen LD; Bjarnsholt T; Calum H; Jensen PØ; Christophersen L; Hougen HP; Ciofu O; Molin S; Givskov M; Høiby N
    J Antimicrob Chemother; 2009 Dec; 64(6):1241-50. PubMed ID: 19815632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo.
    Russo TA; MacDonald U; Beanan JM; Olson R; MacDonald IJ; Sauberan SL; Luke NR; Schultz LW; Umland TC
    J Infect Dis; 2009 Feb; 199(4):513-21. PubMed ID: 19143563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance.
    Gordon NC; Wareham DW
    Int J Antimicrob Agents; 2010 Mar; 35(3):219-26. PubMed ID: 20047818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.